Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluering af Lasofoxifen kombineret med Abemaciclib sammenlignet med Fulvestrant kombineret med Abemaciclib i lokalt avanceret eller metastatisk ER+/HER2- Brystkræft med en ESR1-mutation (ELAINEIII)

10. november 2026 opdateret af: LeonaBio

Et åbent, randomiseret, multicenter-studie, der sammenligner effektiviteten og sikkerheden af ​​kombinationen af ​​Lasofoxifen og Abemaciclib med kombinationen af ​​Fulvestrant og Abemaciclib til behandling af præ- og postmenopausale kvinder og mænd med lokalt avanceret eller metastatisk ER+/HER2-brystkræft med en ESR1-mutation

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation.

The main question the study aims to answer is:

• To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

600

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Simon Daggett - Senior Vice President, Clinical Operations
  • Telefonnummer: (425) 620-8772 (909) 374-3793
  • E-mail: clinicaltrials@leonabio.com

Studiesteder

      • Blacktown, Australien
      • Concord, Australien
      • South Brisbane, Australien
        • Rekruttering
        • Mater Misericordiae Ltd, South Brisbane
        • Kontakt:
    • Ontario
      • Ottawa, Ontario, Canada
        • Rekruttering
        • The Ottawa General Hospital
        • Kontakt:
      • Toronto, Ontario, Canada
        • Rekruttering
        • Sunnybrook Health Sciences Centre -Bayview Campus
        • Kontakt:
    • Quebec
      • Montreal, Quebec, Canada
      • Montreal, Quebec, Canada
      • Saguenay, Quebec, Canada
        • Trukket tilbage
        • CIUSSS du Saguenay-Lac-Saint-Jean
      • Cardiff, Det Forenede Kongerige, CF14 2TL
      • Harlow, Det Forenede Kongerige, CM20 1QX
        • Rekruttering
        • Princess Alexandra Hospital - Harlow
        • Kontakt:
      • Leeds, Det Forenede Kongerige
      • London, Det Forenede Kongerige
        • Rekruttering
        • Charing Cross Hospital
        • Kontakt:
      • London, Det Forenede Kongerige, NW3 2
        • Rekruttering
        • Royal Free London NHS Foundation Trust
        • Kontakt:
      • Manchester, Det Forenede Kongerige
      • Milton Keynes, Det Forenede Kongerige, MK6 5LD
      • Nottingham, Det Forenede Kongerige
      • Stockton-on-Tees, Det Forenede Kongerige, TS198PE
        • Trukket tilbage
        • University Hospital of North Tees
    • Arizona
      • Scottsdale, Arizona, Forenede Stater, 85259
        • Rekruttering
        • Mayo Clinic - Scottsdale
        • Kontakt:
          • Clinical Trials Office - All Mayo Clinic Locations
          • Telefonnummer: 855-776-0015
      • Tucson, Arizona, Forenede Stater, 85719
        • Rekruttering
        • University of Arizona - Cancer Center
        • Kontakt:
    • California
      • Santa Rosa, California, Forenede Stater, 95403
        • Rekruttering
        • Providence Medical Foundation - Santa Rosa, CA
        • Kontakt:
    • Florida
      • Jacksonville, Florida, Forenede Stater, 32224
        • Rekruttering
        • Mayo Clinic - Jacksonville
        • Kontakt:
          • Clinical Trials Office - All Mayo Clinic Locations
          • Telefonnummer: 855-776-0015
      • Miami, Florida, Forenede Stater, 33143
      • Plantation, Florida, Forenede Stater, 33324
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
    • Kentucky
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21231
        • Rekruttering
        • Johns Hopkins Kimmel Cancer Center
        • Kontakt:
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
      • Boston, Massachusetts, Forenede Stater, 02215
        • Afsluttet
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Forenede Stater, 02115
    • Michigan
      • Grand Rapids, Michigan, Forenede Stater, 49503
        • Rekruttering
        • Cancer and Hematology Centers of Western Michigan
        • Kontakt:
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55407
        • Afsluttet
        • Allina Health System DBA Virginia Piper Cancer Institute
      • Rochester, Minnesota, Forenede Stater, 55905
        • Rekruttering
        • Mayo Clinic - Rochester
        • Kontakt:
          • Clinical Trials Office - All Mayo Clinic Locations
          • Telefonnummer: 855-776-0015
    • Missouri
      • Kansas City, Missouri, Forenede Stater, 64111
        • Rekruttering
        • Saint Luke's Cancer Institute
        • Kontakt:
      • St Louis, Missouri, Forenede Stater, 63110
        • Rekruttering
        • Washington University School of Medicine
        • Kontakt:
    • Nevada
      • Reno, Nevada, Forenede Stater, 89502
      • Reno, Nevada, Forenede Stater, 89511-2250
    • New Jersey
      • Belleville, New Jersey, Forenede Stater, 07109
        • Trukket tilbage
        • New Jersey Cancer Care, PA
      • New Brunswick, New Jersey, Forenede Stater, 08901
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87110
        • Ikke rekrutterer endnu
        • Presbyterian Kaseman Hospital
        • Kontakt:
      • Rio Rancho, New Mexico, Forenede Stater, 87124
        • Rekruttering
        • Presbyterian Rust Cancer Center
        • Kontakt:
    • New York
      • New York, New York, Forenede Stater, 10029
        • Rekruttering
        • Icahn School of Medicine at Mount Sinai
        • Kontakt:
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
        • Kontakt:
      • New York, New York, Forenede Stater, 10011
        • Rekruttering
        • The Blavatnik Family - Chelsea Medical Center at Mount Sinai
        • Kontakt:
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27705
        • Rekruttering
        • Duke University Medical Center
        • Kontakt:
    • North Dakota
      • Grand Forks, North Dakota, Forenede Stater, 58201
        • Afsluttet
        • Altru Health Systems
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44106
      • Cleveland, Ohio, Forenede Stater, 44119
        • Trukket tilbage
        • Cleveland Clinic
      • Columbus, Ohio, Forenede Stater, 42112
        • Rekruttering
        • The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James)
        • Kontakt:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15232
        • Afsluttet
        • University of Pittsburgh Medical Center
    • Texas
      • Houston, Texas, Forenede Stater, 77030
      • Houston, Texas, Forenede Stater, 77030
      • Houston, Texas, Forenede Stater, 77054
        • Rekruttering
        • Harris Health System - Smith Clinic
        • Ledende efterforsker:
          • Ahmed Elkhanany
        • Kontakt:
    • Washington
      • Seattle, Washington, Forenede Stater, 98104
        • Trukket tilbage
        • Swedish Cancer Institute (SCI)
      • Afula, Israel, 1834111
      • Beersheba, Israel, 8486614
      • Haifa, Israel
      • Jerusalem, Israel
      • Jerusalem, Israel
        • Rekruttering
        • Hadassah Ein-Karem Medical Center
        • Kontakt:
      • Kfar Saba, Israel, 4428164
      • Petah Tikva, Israel
      • Rehovot, Israel
        • Rekruttering
        • Kaplan Medical Center
        • Kontakt:
      • Tel Aviv, Israel
        • Rekruttering
        • Tel Aviv Sourasky Medical Center
        • Kontakt:
      • Tel HaShomer, Israel
      • Ancona, Italien
      • Aviano, Italien
      • Candiolo, Italien, 10060
      • Meldola, Italien
        • Rekruttering
        • IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l.
        • Kontakt:
      • Milan, Italien
      • Misterbianco, Italien
      • Modena, Italien
        • Rekruttering
        • Azienda Ospedaliero-Universitaria di Modena
        • Kontakt:
      • Naples, Italien
      • Novara, Italien, 28100
        • Trukket tilbage
        • Azienda Ospedaliero Universitaria Maggiore Della Carita
      • Padova, Italien, 35128
        • Rekruttering
        • Istituto Oncologico Veneto-I.R.C.C.S. - Ospedale Busonera
        • Kontakt:
      • Parma, Italien
      • Pavia, Italien
        • Rekruttering
        • Fondazione IRCCS Policlinico San Matteo
        • Ledende efterforsker:
          • Gianpiero Rizzo
        • Kontakt:
      • Roma, Italien
      • Verona, Italien
        • Afsluttet
        • Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
      • Anhui, Kina
        • Rekruttering
        • Anhui Provincial Cancer Hospital
        • Kontakt:
      • Anyang, Kina
      • Beijing, Kina
        • Rekruttering
        • Peking Union Medical College Hospital
        • Kontakt:
      • Beijing, Kina
      • Bengbu, Kina
        • Rekruttering
        • The First Affiliated Hospital of Bengbu Medical University
        • Kontakt:
      • Changchun, Kina
        • Rekruttering
        • The First Hospital of Jilin University
        • Kontakt:
      • Changsha, Kina
        • Rekruttering
        • The Second Xiangya Hospital of Central South University
        • Kontakt:
      • Chengdu, Kina
        • Rekruttering
        • Sichuan Provincial People's Hospital
        • Kontakt:
      • Chengdu, Kina
        • Rekruttering
        • West China Hospital, Sichuan University
        • Kontakt:
      • Chongqicun, Kina
        • Rekruttering
        • The First Affiliated Hospital, Chongqing Medical University
        • Kontakt:
      • Dalian, Kina
        • Rekruttering
        • The Second Hospital of Dalian Medical University
        • Kontakt:
      • Deyang, Kina
        • Rekruttering
        • Deyang People's Hospital
        • Kontakt:
      • Fuyang, Kina
        • Rekruttering
        • Fuyang Cancer Hosptial
        • Kontakt:
      • Fuzhou, Kina
        • Rekruttering
        • Fujian Cancer Hospital
        • Kontakt:
      • Fuzhou, Kina
        • Rekruttering
        • Fujian Medical University Union Hospital
        • Kontakt:
      • Guandong, Kina
        • Rekruttering
        • Zhujiang Hospital of Nanfang Medical University
        • Kontakt:
      • Guangdong, Kina
        • Rekruttering
        • Guangdong Provincial People's Hospital
        • Kontakt:
      • Guangdong, Kina
        • Rekruttering
        • Meizhou People's Hospital
        • Kontakt:
      • Guangdong, Kina
        • Rekruttering
        • Peking University Shenzhen Hospital
        • Kontakt:
          • Xiaoling Liu
      • Guangdong, Kina
        • Rekruttering
        • Sun Yat-Sen University- Cancer Center
        • Kontakt:
      • Guangzhou, Kina
        • Rekruttering
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
        • Kontakt:
      • Haikou, Kina
        • Rekruttering
        • The First Affiliated Hospital of Hainan Medical University
        • Kontakt:
      • Hangzhou, Kina
        • Rekruttering
        • The First Affiliated Hospital, College of Medicine, Zhejiang University
        • Kontakt:
      • Hangzhou, Kina
        • Rekruttering
        • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
        • Kontakt:
      • Hangzhou, Kina
        • Rekruttering
        • Zhejiang Provincial Hospital of Chinese Medicine
        • Kontakt:
      • Hebei, Kina
        • Rekruttering
        • Hebei Medical University - The Fourth Hospital - Hebei Provincial Tumor Hospital
        • Kontakt:
      • Hubei, Kina
        • Rekruttering
        • Xiangyang Central Hospital
        • Kontakt:
      • Hunan, Kina
        • Rekruttering
        • Xiangya Hospital Central South University
        • Kontakt:
      • Jieyang, Kina
        • Rekruttering
        • Jieyang People's Hospital
        • Kontakt:
      • Jinan, Kina
        • Rekruttering
        • Shandong Province Tumor Hospital
        • Kontakt:
      • Kunming, Kina
        • Rekruttering
        • Yunnan Cancer Hospital
        • Kontakt:
      • Lanzhou, Kina
        • Rekruttering
        • The First Hospital of Lanzhou University
        • Kontakt:
      • Lanzhou, Kina
        • Rekruttering
        • Gansu Provincial Hospital
        • Kontakt:
      • Linyi, Kina
        • Rekruttering
        • Linyi Cancer Hospital
        • Kontakt:
      • Luoyang, Kina
        • Rekruttering
        • The First Affiliated Hospital of Henan University of Science and Technology
        • Kontakt:
      • Luoyang, Kina
        • Rekruttering
        • Luoyang Central Hospital
        • Kontakt:
      • Luzhou, Kina
        • Rekruttering
        • The Affiliated Hospital of Southwest Medical University (Luzhou Medical College)
        • Kontakt:
      • Nanchang, Kina
        • Rekruttering
        • Jiangxi Cancer Hospital
        • Kontakt:
      • Nanchang, Kina
        • Rekruttering
        • Nanchang People's Hospital
        • Kontakt:
      • Nanjing, Kina
        • Rekruttering
        • Nanjing Drum Tower Hospital
        • Kontakt:
      • Nanjing, Kina
        • Rekruttering
        • Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University
        • Kontakt:
      • Nanning, Kina
        • Rekruttering
        • Guangxi Medical University Cancer Hospital
        • Kontakt:
      • Nanyang, Kina
        • Rekruttering
        • Nanyang Central Hospital
        • Kontakt:
      • Neijiang, Kina
        • Rekruttering
        • The Second People's Hospital of Neijiang
        • Kontakt:
      • Ningbo, Kina
        • Rekruttering
        • Ningbo Medical Center Li Huili Hospital
        • Kontakt:
      • Pingdingshan, Kina
        • Rekruttering
        • The First People'S Hospital of Ping Ding Shan
        • Kontakt:
      • Qingdao, Kina
        • Rekruttering
        • The Affiliated Hospital of Qingdao University
        • Kontakt:
      • Qingdao, Kina
        • Rekruttering
        • Qingdao Central Hospital, University of Health and Rehabilitation Sciences
        • Kontakt:
      • Quanzhou, Kina
        • Rekruttering
        • Quanzhou First Hospital
        • Kontakt:
      • Shanghai, Kina
        • Rekruttering
        • Huashan Hospital, Fudan University
        • Kontakt:
      • Shanghai, Kina
        • Rekruttering
        • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
        • Kontakt:
      • Shang’ai, Kina
        • Rekruttering
        • Fudan University Cancer Center
        • Kontakt:
      • Shanxi, Kina
        • Rekruttering
        • First Affiliated Hospital of Xi'an Jiaotong University
        • Kontakt:
      • Shaoyang, Kina
        • Rekruttering
        • The Central Hospital of Shaoyang
        • Kontakt:
      • Shenyang, Kina
        • Rekruttering
        • Liaoning Cancer Hospital & Institute
        • Kontakt:
      • Shouguang, Kina
        • Rekruttering
        • Yuebei People's Hospital
        • Kontakt:
      • Sichuan, Kina
        • Rekruttering
        • University of Electonic Science & Technology (UESTC) - Sichuan Cancer Hospital & Institute
        • Kontakt:
      • Tianjin, Kina
        • Rekruttering
        • Tianjin Medical University Cancer Institute & Hospital
        • Kontakt:
      • Tianjin, Kina
        • Rekruttering
        • Tianjin Cancer Hospital Airport Hospital
        • Kontakt:
      • Wenzhou, Kina
        • Rekruttering
        • The First Affiliated Hospital of Wenzhou Medical University
        • Kontakt:
      • Wuhan, Kina
        • Rekruttering
        • Hubei Cancer Hospital
        • Kontakt:
      • Wuhan, Kina
        • Rekruttering
        • Union Hospital Tongji Medical College Huazhong University of Science and Technolog
        • Kontakt:
      • Wuhu, Kina
        • Rekruttering
        • The Second People's Hospital of WuHu
        • Kontakt:
      • Xi Ail, Kina
        • Rekruttering
        • The First Affiliated Hospital of Air Force Medical University
        • Kontakt:
      • Xiamen, Kina
        • Rekruttering
        • Zhongshang Hospital Xiamen University
        • Kontakt:
      • Xiamen, Kina
        • Rekruttering
        • The first affiliated hospital of Xiamen University
        • Kontakt:
      • Xinzheng, Kina
        • Rekruttering
        • The Second Affiliated Hospital Of Xi'an Jiaotong University
        • Kontakt:
      • Xuzhou, Kina
        • Rekruttering
        • The Affiliated Hospital of Xuzhou Medical University
        • Kontakt:
      • Xuzhou, Kina
        • Rekruttering
        • Xuzhou Central Hospital
        • Kontakt:
      • Yuncheng, Kina
        • Rekruttering
        • Yuncheng Central Hospital
        • Kontakt:
      • Zhejiang, Kina
        • Rekruttering
        • Zhejiang Provincial People's Hospital
        • Kontakt:
      • Zhejiang, Kina
        • Rekruttering
        • Zhejiang cancer hospital
        • Kontakt:
      • Zhengzhou, Kina
        • Rekruttering
        • Henan Cancer Hospital
        • Kontakt:
      • Zhengzhou, Kina
        • Rekruttering
        • The First Affiliated Hospital of Zhengzhou University
        • Kontakt:
      • Zhongshan, Kina
        • Rekruttering
        • Zhongshan City People's Hospital
        • Kontakt:
      • Zhumadian, Kina
        • Rekruttering
        • Zhumadian Central Hospital
        • Kontakt:
      • Ürümqi, Kina
        • Rekruttering
        • The Affiliated Cancer Hospital of Xinjiang Medical University
        • Kontakt:
      • Biała Podlaska, Polen
        • Trukket tilbage
        • KO - MED Centra Kliniczne Sp. z o.o., Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej
      • Gliwice, Polen
        • Trukket tilbage
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, I Klinika Radioterapii i Chemioterapii
      • Krakow, Polen
        • Rekruttering
        • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie - Oddzial Onkologii Klinicznej z Pododdzialem Dziennym
        • Kontakt:
      • Krakow, Polen
      • Lodz, Polen
        • Afsluttet
        • Instytut Centrum Zdrowia Matki Polki - Klinika Onkologii
      • Poznan, Polen
        • Rekruttering
        • Uniwersytecki Szpital Kliniczny w Poznaniu, Oddzial Chemioterapii
        • Kontakt:
      • Poznan, Polen
        • Rekruttering
        • Wielkopolskie Centrum Onkologii (WCO) / The Greater Poland Cancer Center
        • Kontakt:
      • Wieliszew, Polen
      • Bucharest, Rumænien
        • Rekruttering
        • Memorial Healthcare International SRL
        • Kontakt:
      • Bucharest, Rumænien
        • Trukket tilbage
        • Centrul Medical Focus
      • Cluj-Napoca, Rumænien
      • Craiova, Rumænien
        • Rekruttering
        • Oncology Center Sfantul Nectarie
        • Kontakt:
      • Craiova, Rumænien
        • Afsluttet
        • Onco Clinic Consult SA
      • Piteşti, Rumænien
      • Timișoara, Rumænien
        • Rekruttering
        • OncoMed Oncology Center
        • Kontakt:
      • Barcelona, Spanien
        • Rekruttering
        • Hospital Universitario Vall d'Hebron
        • Kontakt:
      • Barcelona, Spanien
      • Córdoba, Spanien
        • Rekruttering
        • Hospital Universitario Reina Sofia
        • Kontakt:
      • Madrid, Spanien, 28034
        • Rekruttering
        • Hospital Universitario Ramon y Cajal
        • Kontakt:
      • Madrid, Spanien, 28040
      • Madrid, Spanien
        • Rekruttering
        • Hospital Universitario 12 de Octubre
        • Kontakt:
      • Madrid, Spanien
      • Madrid, Spanien
        • Rekruttering
        • Clinica Universidad de Navarra - Madrid
        • Kontakt:
      • Madrid, Spanien
        • Rekruttering
        • Hospital Beata Maria Ana
        • Kontakt:
      • Madrid, Spanien
        • Rekruttering
        • Hospital General Universitario Gregorio Maranon
        • Kontakt:
      • Málaga, Spanien
      • Pamplona, Spanien
        • Rekruttering
        • Clinica Universidad de Navarra - Pamplona
        • Kontakt:
      • Valencia, Spanien
        • Rekruttering
        • Instituto Valenciano de Oncologia
        • Kontakt:
      • Gyeonggi-do, Sydkorea
        • Rekruttering
        • National Cancer Center
        • Kontakt:
      • Jeollanam-do, Sydkorea, 58128
        • Rekruttering
        • Chonnam National University Hwasun Hospital
        • Kontakt:
      • Seoul, Sydkorea
        • Rekruttering
        • Korea University Anam Hospital
        • Kontakt:
      • Seoul, Sydkorea
        • Trukket tilbage
        • Severance Hospital, Yonsei University Health System
      • Seoul, Sydkorea
        • Trukket tilbage
        • Asan Medical Center
      • Changhua, Taiwan
        • Rekruttering
        • Changhua Christian Hospital (CCH)
        • Kontakt:
      • Kaohsiung City, Taiwan
        • Rekruttering
        • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
        • Kontakt:
      • Tainan, Taiwan
        • Rekruttering
        • National Cheng Kung University Hospital
        • Kontakt:
      • Taipei, Taiwan
        • Rekruttering
        • National Taiwan University Hospital
        • Kontakt:
      • Taipei, Taiwan
        • Rekruttering
        • Tri-Service General Hospital
        • Kontakt:
      • Taipei, Taiwan
        • Rekruttering
        • Koo Foundation Sun Yat-Sen Cancer Center
        • Kontakt:
      • Taoyuan City, Taiwan
      • Ankara, Tyrkiet (Türkiye)
        • Rekruttering
        • Ankara University Medical Faculty Medical Oncology Department
        • Kontakt:
      • Bursa, Tyrkiet (Türkiye)
        • Rekruttering
        • Uludag University Faculty of Medicine Hospital
        • Kontakt:
      • Edirne, Tyrkiet (Türkiye)
      • Izmir, Tyrkiet (Türkiye)
    • Ankara
      • Çankaya, Ankara, Tyrkiet (Türkiye)
    • Istanbul
      • Kadiköy, Istanbul, Tyrkiet (Türkiye)
        • Rekruttering
        • Goztepe Prof. Dr. Suleyman Yalcin City Hospital
        • Kontakt:
      • Çapa, Istanbul, Tyrkiet (Türkiye)
    • Kocaeli
    • İzmir
      • Bornova, İzmir, Tyrkiet (Türkiye)
        • Rekruttering
        • Ege University Medical Faculty Hospital
        • Kontakt:
      • Konak, İzmir, Tyrkiet (Türkiye)
      • Dresden, Tyskland
      • München, Tyskland
        • Rekruttering
        • Klinikum rechts der Isar der Technischen Universitaet Muenchen
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Pre- or postmenopausal women or men.

  2. Locally advanced and/or metastatic ER+ breast cancer with radiological or clinical evidence of progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease.

  3. Histological or cytological confirmation of ER+/HER2 - disease

  4. No evidence of progression for at least 6 months on an AI/CDKi combination for advanced breast cancer.

  5. At least 1 or more ESR1 point mutations in the ESR1 ligand binding domain as assessed in cell- free ctDNA obtained from a blood or breast cancer tissue.

  6. Locally advanced or metastatic breast cancer with at least 1 measurable (according to RECIST 1.1) lesion with or without non-measurable lesions.

  7. Subjects may have received 1 cytotoxic chemotherapy regimen in the metastatic disease setting prior to study entry, but must have recovered from chemotherapy acute toxicity excluding alopecia and Grade 2 peripheral neuropathy.

  8. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1

  9. Adequate organ function

  10. Able to swallow tablets

  11. Brain metastases are allowed only if the following 4 parameters hold:

    1. Asymptomatic,
    2. Definitively treated (e.g., radiotherapy, surgery),
    3. Not requiring steroids up to 4 weeks before study treatment initiation, AND
    4. Central nervous system disease stable for >3 months prior to registration as documented by magnetic resonance imagining (MRI).
  12. Able to understand and voluntarily sign a written informed consent before any screening procedures.

  13. Every attempt should be made to obtain a biopsy of metastatic breast cancer tissue, when safe and feasible, to provide histological or cytological confirmation of ER+/HER2- disease as assessed by a local laboratory, according to American Society of Clinical Oncology/College of American Pathologists guidelines, using slides, paraffin blocks, or paraffin samples. If a biopsy is done, it may undergo genomic testing at some point to assess for ESR1 mutations and correlation with ctDNA results. If a biopsy is not possible or inappropriate from a clinical standpoint, the ER and HER2 status from the subject's most recent biopsy must confirm that the subject is ER+ and HER2

Exclusion Criteria:

  1. Lymphangitic carcinomatosis involving the lung.
  2. History of Grade 3 or Grade 4 interstitial lung disease (ILD) on previous therapy.
  3. Visceral crisis in need of cytotoxic chemotherapy as assessed by the investigator.
  4. Prior progression of disease on abemaciclib, fulvestrant, or other selective estrogen receptor degrader (SERD) therapy.
  5. Subjects with a known hypersensitivity to fulvestrant or to any of the excipients
  6. Radiotherapy within 30 days prior to Visit 0 (Day 1) except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to Visit 0 (Day 1). Subjects must have recovered from radiotherapy toxicities prior to Visit 0 (Day 1).
  7. Known RB1 mutations or deletions that in the opinion of the investigator confer resistance to CDK4/6i. (Screening for RB1 mutation is not required for entry.)
  8. History of long QTc (Q-T interval corrected for heart rate) syndrome or a QTc of >480 msec.
  9. History of a pulmonary embolus (PE), deep vein thrombosis (DVT), or any known thrombophilia, unless the event occurred greater than 6 months prior to screening and the subject is treated with chronic anticoagulant therapy such as apixaban (Eliquis) or rivaroxaban (Xarelto).
  10. Lasofoxifene is not recommended for use in subjects with conditions that place them at increased risk for VTEs (such as severe congestive heart failure [CHF] or prolonged immobilization).
  11. On concomitant strong CYP3A4 inhibitors.
  12. On strong and moderate CYP3A4 inducers.
  13. Any significant co-morbidity that would impact the study or the subject's safety, including subjects with significant malabsorption.
  14. Active systemic bacterial or fungal infection (requiring intravenous [IV] antibiotics or antifungals at the time of initiating study treatment).
  15. Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).
  16. History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery.
  17. Positive serum pregnancy test (only if premenopausal).
  18. Sexually active premenopausal women and men unwilling to use double-barrier contraception.
  19. Women who are breast feeding
  20. History of non-compliance to medical regimens.
  21. Unwilling or unable to comply with the protocol.
  22. Current participation in any clinical research trial involving an investigational drug or device within the last 30 days.
  23. Subjects with a history of familial hypertriglyceridemia or fasting triglyceride levels >880 mg/dL at screening.
  24. Fasting triglyceride level >300 mg/dL and ≤880 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting triglyceride level less than or equal to 300 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).
  25. Fasting cholesterol level >400 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting cholesterol level less than or equal to 400 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Treatment

Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.

5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day

Aktiv komparator: Reference Therapy

Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.

Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression free survival (PFS)
Tidsramme: Within approximately 3 years

PFS is defined as the time from the date of randomization [Visit 0 (Day 1)] to the earliest date of first documented progression per RECIST 1.1 as determined by BICR or death due to any cause.

Within approximately 3 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Objective response rate (ORR)
Tidsramme: Within approximately 3 years

ORR is defined as the percentage of subjects with measurable disease at baseline whose best overall response is either a confirmed CR or a confirmed PR according to RECIST 1.1.

Within approximately 3 years
Overall survival (OS)
Tidsramme: Within approximately 3 years

Overall survival is defined as time from the date of Visit 0 (Day 1) to death due to any cause.

Within approximately 3 years
Clinical benefit rate (CBR)
Tidsramme: Within approximately 3 years

CBR is defined as the percentage of subjects with best overall response of confirmed CR, confirmed PR, or stable disease (SD) with a duration of 24 weeks or longer according to RECIST 1.1. As used in this calculation, stable disease is defined as stable disease in those subjects with measurable disease plus nonPR/non progressive disease (PD) in subjects with non-measurable disease.

Within approximately 3 years
Duration of response (DoR) in subjects with an objective response
Tidsramme: Within approximately 3 years

DoR is from the date of first documented confirmed response (CR or PR) to the date of first documented progression of disease or death due to any cause, whichever is earlier.

Within approximately 3 years
Time to response (TTR) in subjects with an objective response
Tidsramme: Within approximately 3 years

TTR is from the date of randomization to the date of first documented confirmed response (CR or PR).

Within approximately 3 years
Time to cytotoxic chemotherapy
Tidsramme: Within approximately 3 years

From the date of randomization to the date of first documented use of cytotoxic chemotherapy.

Within approximately 3 years
Quality of Life (QoL) evaluated using the Functional Assessment of Cancer Therapy-Breast Cancer-Endocrine Subscale (FACT B-ES)
Tidsramme: Within approximately 3 years

Scale ranges from 'Not at all' to 'Very much'

Within approximately 3 years
Incidence of Adverse Events (AEs) and Serious AEs
Tidsramme: Within approximately 3 years

The type, severity (graded by Common Terminology Criteria for Adverse Events [CTCAE version 5.0]), course, duration, seriousness, and relationship to study treatment will be assessed at each visit

Within approximately 3 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

31. oktober 2023

Primær færdiggørelse (Anslået)

1. april 2027

Studieafslutning (Anslået)

1. april 2028

Datoer for studieregistrering

Først indsendt

13. januar 2023

Først indsendt, der opfyldte QC-kriterier

13. januar 2023

Først opslået (Faktiske)

25. januar 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

13. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner